Sort
51,593 grants matching “hepatitis”
Multiple Ascending Dose clinical trial of PTI-125, a novel AD therapeutic candidate
$2,896,561Lindsay H Burns · Cassava Sciences, Inc · R44 · FY2019 · AG
MULTICENTER AIDS COHORT STUDY
$2,884,097Howard Brown Health Center · U01 · FY2005 · AI
IeDEA Asia-Pacific Research Collaboration
$2,883,099Annette H Sohn · Foundation For Aids Research · U01 · FY2024 · AI
Addressing risk through Community Treatment for Infectious disease and Opioid use disorder Now (ACTION) among justice-involved populations
$2,880,406Sandra Ann Springer · Yale University · U01 · FY2022 · DA
Project 3: Pandemic Virus Protease Inhibitors
$2,879,997Reuben S Harris · University Of Minnesota · U19 · FY2022 · AI
Non-invasive etiology-adjusted precision liver cancer risk prediction
$2,876,456Yujin Hoshida · Ut Southwestern Medical Center · R01 · FY2025 · CA
Mechanisms of immune Failure in Chronic Infection: Hepatitis C as a Key Paradigm
$2,874,928Raymond T Chung · Massachusetts General Hospital · U19 · FY2011 · AI
Southern California Women's Interagency HIV Study Consortium
$2,871,520Marek Jan Nowicki · University Of Southern California · U01 · FY2010 · HD
Discovery of New Innate Immune Pathways in Viral Recognition
$2,863,677Jenny P.y. Ting · Univ Of North Carolina Chapel Hill · U19 · FY2017 · AI
Discovery of New Innate Immune Pathways in Viral Recognition
$2,863,677Jenny P.y. Ting · Univ Of North Carolina Chapel Hill · U19 · FY2015 · AI
Role of G protein-coupled receptors in regulating glucose and energy homeostasis
$2,863,394Jurgen Wess · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2020 · DK
TREATMENT OF ADDICTIONS--BIOLOGICAL CORRELATES
$2,856,886Rockefeller University · P60 · FY2003 · DA
Durban International Clinical Trials Unit
$2,855,468Umesh G Lalloo · University Of Kwazulu-Natal · U01 · FY2009 · AI
Defining signatures for immune responsiveness by functional systems immunology
$2,849,006David A. Hafler · Yale University · U19 · FY2011 · AI
GE Healthcare Discovery MR750 3T MRI System
$2,848,680Frank Korosec · University Of Wisconsin-Madison · S10 · FY2010 · RR
Integrating innate and adaptive pathways in vaccine responses
$2,848,678Jeffrey Victor Ravetch · Rockefeller University · U19 · FY2018 · AI
NIAID VIROLOGY QUALITY ASSURANCE (VQA)
$2,848,397Thomas Denny · Duke University · N01 · FY2020 · AI
Southern California Women's Interagency HIV Study Consortium
$2,845,866Marek Jan Nowicki · University Of Southern California · U01 · FY2009 · HD
Impact of CAR and Nrf2 dual activation on cyclophosphamide bioactivation and doxorubicin detoxification
$2,840,768Hongbing Wang · University Of Maryland Baltimore · R01 · FY2025 · CA
Defining signatures for immune responsiveness by functional systems immunology
$2,837,004David A. Hafler · Yale University · U19 · FY2012 · AI
Defining signatures for immune responsiveness by functional systems immunology
$2,834,344David A. Hafler · Yale University · U19 · FY2014 · AI
Metabolic Regulation by SAPS3 of Virus-specific T cell Immunity
$2,832,747Roberto Tinoco · University Of California-Irvine · R01 · FY2025 · AI
Clinical Genomics and Experimental Therapeutics
$2,830,248Falk Lohoff · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2020 · AA
The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit
$2,828,231Beatriz Grinsztejn · Fundacao Oswaldo Cruz · UM1 · FY2019 · AI
Wits HIV Research Group CLINICAL TRIAL UNIT (CTU) reapplication
$2,826,477Ian Matthias Sanne · Wits Health Consortium (Pty), Ltd · UM1 · FY2022 · AI